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Hypertension, dyslipidemia, and smoking are all factors that 
increase the risk of cardiovascular disease in patients with type 
2 diabetes [1]. Among them, one of the most important risk 
factors is dyslipidemia.
  Among lipoproteins, low density lipoprotein cholesterol 
(LDL-C) level is the most important predicting factors for car-
diovascular disease, and many large-scale studies have been 
ongoing for many years to determine the target value for LDL-
C treatment [2]. Since the risk of cardiovascular disease in 
type 2 diabetes patients is higher than that in healthy, the tar-
get LDL-C value in diabetes patients has been emphasized as 
being even more important than other metrics [3]. When the 
recommended LDL-C treatment goals of the 2003 Adult Treat-
ment Panel III (ATP III) of the National Cholesterol Education 
Program (NCEP) and the 2008 American Diabetes Associa-
tion (ADA) released consensus with the American College of 
Cardiology (ACC) [4] and the dyslipidemia treatment goal 
guidelines in accordance with the 2011 European Society of 
Cardiology (ESC) and the European Society of Arteriosclero-
sis (ESA) were examined, recent trends generally call for more 
aggressive LDL-C reduction than what has been seen in previ-
ous guidelines particularly in the patient group with the high-
est risk, where an LDL-C target value less than 70 mg/dL is en-
couraged [5]. Based on the ESC and the ESA guidelines, car-
diovascular disease, severe chronic kidney disease, and target 
organ damage are all included in the highest risk factors for 
the diabetes group. Even when diabetes is the only risk factor, 
the target value for LDL-C is recommended to be less than 70 
mg/dL [5].
  The LDL-C treatment target values have gradually been get-
ting more aggressive all over the world. Although the changes 
in these values are aggressive, there is no set guideline for 
LDL-C treatment target values in Koreans, specifically Kore-
ans who have diabetes. There are also very few studies that 
show the actual level of success of dyslipidemia treatment ac-
cording to this guideline or how effectively the treatment tar-
get value is achieved (achievement rate). Hwang et al. [6] per-
formed a study on diabetes patients over 18 years of age who 
were receiving treatment for hyperlipidemia. Research was 
conducted on the difference between the achievement rate of 
actual treatment target value of LDL-C and recognition rate of 
target values by medical personnel (expected achievement 
rate). Among the patients who had received treatment, 35.9% 
(approximately 1/3 of the total participants) reached the actual 
LDL-C target value, while that the expected achievement rate 
was reported in 70.6% of the total participants. In addition, 
even when lipid levels did not reach the target value, 65.3% of 
patients were receiving the same statin dosage as when the 
treatment was started. The authors felt that these results were 
due to a lack of recognition of the target lipid values by the 
medical personnel. So, in order to decrease the risk of cardio-
vascular disease in Korean diabetes patients and in order for 
LDL-C treatment goals to be reached, they proposed that the 
recognition standards of the medical personnel be changed [6].
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  A limitation to this study is that they did not consider wheth-
er participants performed any sort of diet or exercise, and drug 
compliance was also not considered. In actual clinical practice, 
it could easily be seen that lipid levels did not reach the target 
values, and clinicians were able to provide adequate care. In 
particular, in diabetes patients at relatively high risk for cardio-
vascular disease, statin dosage is increased, being able to reach 
the target value is the most feasible basis. In the future, even 
when patients receive treatment, prospective studies regarding 
the difficulty to reach the lipid target value (due to the low suc-
cess rate) are required. In addition, during dyslipidemia treat-
ment, statin drug therapy is not the only treatment method 
used; diet management and exercise are often combined with 
the treatment process. Additional studies on other positive ef-
fects, the need for education, and effectiveness of these treat-
ments will be very helpful in the treatment of dyslipidemia.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was re-
ported.
REFERENCES
1. Webb DR, Khunti K, Gray LJ, Srinivasan BT, Farooqi A, Ware-
ham N, Griffin SC, Davies MJ; for the ADDITION-Leicester 
study group. Intensive multifactorial intervention improves 
modelled 5-year coronary heart disease risk in screen-detected 
Type 2 diabetes mellitus: a cluster randomized controlled trial. 
Diabet Med. Epub 2011 Sep 13. DOI: 10.1111/j.1464-5491. 
2011.03441.x.
2. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, 
Faergeman G, Pyorala K, Miettinen T, Wilhelmsen L, Olsson 
AG, Wedel H; Scandinavian Simvastatin Survival Study Group. 
Randomised trial of cholesterol lowering in 4444 patients with 
coronary heart disease: the Scandinavian Simvastatin Survival 
Study (4S). 1994. Atheroscler Suppl 2004;5:81-7.
3. Almdal T, Scharling H, Jensen JS, Vestergaard H. The indepen-
dent effect of type 2 diabetes mellitus on ischemic heart disease, 
stroke, and death: a population-based study of 13,000 men and 
women with 20 years of follow-up. Arch Intern Med 2004;164: 
1422-6.
4. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, 
Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Na-
tional Heart, Lung, and Blood Institute; American College of 
Cardiology Foundation; American Heart Association. Impli-
cations of recent clinical trials for the National Cholesterol Ed-
ucation Program Adult Treatment Panel III guidelines. Circu-
lation 2004;110:227-39.
5. European Association for Cardiovascular Prevention & Reha-
bilitation, Reiner Z, Catapano AL, De Backer G, Graham I, 
Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, 
Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi 
PP, Riccardi G, Storey RF, Wood D; ESC Committee for Prac-
tice Guidelines (CPG) 2008-2010 and 2010-2012 Committees, 
Bax J, Vahanian A, Auricchio A, Baumgartner H, Ceconi C, 
Dean V, Deaton C, Fagard R, Filippatos G, Funck-Brentano C, 
Hasdai D, Hobbs R, Hoes A, Kearney P, Knuuti J, Kolh P, Mc-
Donagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, 
Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vardas P, Wi-
dimsky P, Windecker S, Funck-Brentano C, Poldermans D, 
Berkenboom G, De Graaf J, Descamps O, Gotcheva N, Griffith 
K, Guida GF, Gulec S, Henkin Y, Huber K, Kesaniemi YA, Leka-
kis J, Manolis AJ, Marques-Vidal P, Masana L, McMurray J, 
Mendes M, Pagava Z, Pedersen T, Prescott E, Rato Q, Rosano 
G, Sans S, Stalenhoef A, Tokgozoglu L, Viigimaa M, Wittekoek 
ME, Zamorano JL. ESC/EAS Guidelines for the management 
of dyslipidaemias: the Task Force for the management of dys-
lipidaemias of the European Society of Cardiology (ESC) and 
the European Atherosclerosis Society (EAS). Eur Heart J 2011; 
32:1769-818.
6. Hwang JY, Jung CH, Lee WJ, Park CY, Kim SR, Yoon KH, Lee 
MK, Park SW, Park JY. Low density lipoprotein cholesterol tar-
get goal attainment rate and physicians’ perceptions about tar-
get goal achievement in Korean patients with diabetes. Diabe-
tes Metab J 2011;35:628-36.